公司问答丨百奥泰：托珠单抗皮下制剂已完成临床试验 目前正积极推进申报前各项准备工作

Core Viewpoint - The company Baiotai has completed clinical trials for the subcutaneous formulation of tocilizumab and is actively preparing for the submission of applications both domestically and for overseas authorization [1] Group 1 - The subcutaneous formulation of tocilizumab has completed clinical trials [1] - Baiotai is currently working on preparations for application submissions [1]